Lilly's experimental drug cuts weight by 21% in diabetes trial

2

Sept 29 (Reuters) – Eli Lilly said on Tuesday its experimental drug helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial. (

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)